# FDA Approves Brivaracetam Injection Generic, Expanding Market Competition PAI Pharma has received FDA approval for its generic brivaracetam injection, an intravenous formulation of the antiepileptic drug, potentially opening new market opportunities in the hospital and acute care settings where injectable seizure treatments are critical. The approval of this generic alternative is expected to increase treatment accessibility and create pricing pressure in the injectable antiepileptic market, benefiting healthcare systems and patients seeking cost-effective options for acute seizure management.